List of Excipients in Branded Drug HIZENTRA

HIZENTRA Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 13, 2026

Hizentra is a 20% subcutaneous immunoglobulin product whose commercial differentiation depends on a simple excipient system: L-proline, polysorbate 80, and water for injection. The formulation supports high protein concentration, room-temperature administration, and subcutaneous delivery, while avoiding refrigeration during labeled storage. The strongest commercial opportunities are in excipient supply, high-concentration immunoglobulin formulation, administration devices, home-infusion services, and biosimilar development rather than in conventional generic substitution.

What excipients are used in Hizentra?

Hizentra contains human normal immunoglobulin at 200 mg/mL. Its principal excipients are L-proline, polysorbate 80, and water for injection. The product is formulated at an acidic pH and is supplied as a ready-to-use liquid for subcutaneous administration.[1]

Component	Function in Hizentra	Commercial relevance
Human immunoglobulin	Active biological ingredient	Determines potency, purity, aggregate profile, and supply economics
L-proline	Stabilizer and protein-protection excipient	Supports high-concentration liquid formulation and storage stability
Polysorbate 80	Surfactant	Limits protein adsorption and agitation-induced aggregation
Water for injection	Vehicle	Enables ready-to-use liquid administration
Acidic formulation environment	Supports product stability	Affects tolerability, protein integrity, and comparability requirements

The FDA prescribing information identifies L-proline and polysorbate 80 as inactive ingredients. The formulation does not use a carbohydrate stabilizer such as sucrose or maltose, which reduces the relevance of sugar-associated renal safety considerations but makes protein-stability control more dependent on amino-acid stabilization and surfactant performance.[1]

Why is L-proline important in the Hizentra formulation?

L-proline is the principal formulation differentiator in Hizentra’s excipient system. It is used as a protein stabilizer in a high-concentration immunoglobulin solution. At 200 mg/mL immunoglobulin concentration, the product must control aggregation, viscosity, surface adsorption, and chemical degradation without compromising subcutaneous tolerability.

L-proline can support protein conformational stability and reduce the tendency of immunoglobulin molecules to associate during storage or handling. Its use also allows CSL Behring to avoid a larger excipient system that could increase osmolality, injection discomfort, or manufacturing complexity.

The commercial value of L-proline is therefore greater than its unit cost. A qualified pharmaceutical-grade supplier must support:

• Lot-to-lot purity and identity.
• Low bioburden and endotoxin control.
• Consistent trace-metal profile.
• Compatibility with viral-clearance and aseptic-processing controls.
• Long-term supply under biologics-grade quality agreements.
• Change-control documentation suitable for comparability assessments.

What role does polysorbate 80 play in Hizentra?

Polysorbate 80 protects immunoglobulin against adsorption to manufacturing equipment, vials, syringes, tubing, and infusion components. It also reduces aggregation caused by agitation and air-liquid interfaces during shipping and administration.

Polysorbate 80 creates its own control requirements. It can undergo oxidation and hydrolysis, potentially generating degradants that affect protein quality. A supplier change, raw-material change, or manufacturing-process change may require assessment of:

• Peroxide levels.
• Fatty-acid composition.
• Hydrolytic degradation products.
• Subvisible particles.
• Protein aggregation.
• Antibody binding activity.
• Container-closure compatibility.

This makes polysorbate 80 a quality-critical excipient even though it is present at a low concentration. A commercial supplier with strong analytical controls can compete on impurity profile, consistency, documentation, and global regulatory support rather than price alone.

How does Hizentra’s excipient system support commercial performance?

Hizentra’s excipient strategy supports three product characteristics that have direct commercial value: high concentration, subcutaneous administration, and storage flexibility.

Product attribute	Excipient contribution	Commercial effect
20% protein concentration	L-proline stabilization and surfactant protection	Lower volume per dose than dilute immunoglobulin products
Subcutaneous delivery	Liquid stability and manageable viscosity	Enables home treatment and self-administration
Room-temperature storage	Stable liquid formulation	Reduces dependence on refrigerated distribution
Ready-to-use presentation	No reconstitution excipient system required	Simplifies home use and specialty-pharmacy fulfillment
Multi-site infusion capability	Product tolerability and delivery format	Supports patient-specific dosing and administration schedules

The FDA label permits Hizentra to be stored at room temperature, up to 25°C, for the labeled storage period. This is commercially important because specialty pharmacies, home-infusion providers, and patients can manage inventory without continuous refrigeration under the labeled conditions.[1]

The formulation also supports dosing through multiple subcutaneous infusion sites. Hizentra is administered using an infusion pump or approved administration system, allowing patients to receive treatment outside an infusion center. This shifts value from the drug alone toward the combined product-service model: drug, pump, needles, training, nursing support, specialty distribution, and adherence management.

What FDA regulatory status does Hizentra have?

Hizentra is an FDA-approved biologic, not a conventional small-molecule drug. CSL Behring received FDA approval for primary immunodeficiency diseases in 2010. FDA later approved Hizentra for maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy in 2018.[2][3]

Regulatory event	Date	Significance
FDA approval for primary immunodeficiency	2010	Established Hizentra as a subcutaneous immune globulin product
FDA approval for CIDP maintenance therapy	2018	Expanded the addressable market beyond primary immunodeficiency
Biologic product classification	Ongoing	Creates biosimilar and interchangeable-product considerations rather than ANDA substitution

Hizentra does not have an Orange Book listing in the manner of a conventional small-molecule drug. Biologics are generally tracked through the FDA Purple Book, while patent information may be submitted through the FDA’s biologic patent-listing framework under the Biologics Price Competition and Innovation Act.[4][5]

The absence of an ordinary Orange Book entry means that a generic applicant cannot rely on the standard ANDA Paragraph IV pathway used for small-molecule medicines. A competing product would generally need to pursue a 351(k) biosimilar application or another biologic approval pathway.

When does Hizentra lose exclusivity?

Hizentra’s regulatory exclusivity is separate from its patent exclusivity. The 12-year reference-product exclusivity period for a licensed biologic is measured from the date of first licensure of the reference product, subject to statutory and regulatory treatment of the specific product and indication.[6]

For Hizentra, the principal United States reference-product exclusivity period is associated with the 2010 original biologic approval. That period has elapsed. The 2018 CIDP approval expanded labeling but did not ordinarily create a new 12-year reference-product exclusivity term for the same biologic.

Exclusivity category	Hizentra position
Small-molecule NCE exclusivity	Not applicable
Conventional ANDA exclusivity	Not applicable
Biologic reference-product exclusivity	Original period tied to 2010 licensure; elapsed
Pediatric exclusivity	Requires product-specific FDA determination
Orphan exclusivity	Not the principal commercial protection for Hizentra
Patent protection	Must be assessed separately by patent family and jurisdiction

Loss of biologic exclusivity does not produce automatic market entry. A biosimilar sponsor still must establish high similarity, demonstrate no clinically meaningful differences, satisfy manufacturing requirements, and address any unexpired patent rights.

What patent protection covers Hizentra?

Hizentra’s relevant patent protection can be divided into four categories:

1. Formulation patents covering concentrated immunoglobulin compositions, stabilizers, surfactants, pH, and storage conditions.
2. Method-of-use patents covering subcutaneous immunoglobulin treatment, including disease-specific maintenance therapy.
3. Manufacturing patents covering purification, viral inactivation, concentration, filtration, and protein-stability processes.
4. Device and administration patents covering pumps, cartridges, infusion sets, and delivery configurations.

Patent risk is therefore broader than the composition of matter for human immunoglobulin, which is a biological mixture rather than a conventional proprietary small molecule.

Are Hizentra formulation patents commercially important?

Formulation patents can be important because a biosimilar sponsor may need to develop a different stabilizer system, surfactant level, buffer, container, or administration configuration to avoid infringement. A competitor may still obtain approval with a non-infringing formulation if it demonstrates equivalent quality, safety, and efficacy.

The most commercially relevant claim elements may include:

• Immunoglobulin concentration near 20%.
• L-proline as a stabilizer.
• Polysorbate 80 as a surfactant.
• Acidic pH ranges.
• Low-aggregate liquid formulations.
• Storage at room temperature.
• Subcutaneous administration in defined dose ranges.
• Specific combinations of formulation and delivery device.

Patent strength depends on claim scope, validity, prosecution history, expiration, terminal disclaimers, continuations, and jurisdiction. A narrow claim directed only to a particular excipient concentration may be easier to design around than a broader claim covering a stable high-concentration immunoglobulin composition.

What are the Paragraph IV risks for Hizentra?

A conventional Paragraph IV certification is not the principal pathway for challenging Hizentra because Hizentra is a biologic. A biosimilar sponsor instead evaluates the Purple Book, FDA patent disclosures, patent certifications and notices under the BPCIA, and potential patent litigation under the statutory information-exchange process.[4][6]

A biosimilar challenge may target:

• Formulation patents.
• Manufacturing patents.
• Subcutaneous-use patents.
• CIDP method-of-use patents.
• Device patents.
• Patent claims covering excipient combinations.

A sponsor can seek approval for all reference-product indications or pursue a narrower label that omits a patented method of use. Label carving can reduce litigation exposure where the disputed patent covers only a particular indication or dosing method.

What biosimilar and generic entry risks exist for Hizentra?

The principal entry risk is biosimilar competition, not a traditional generic launch. The manufacturing burden is high because the active ingredient is derived from human plasma and requires control of donor screening, fractionation, purification, viral clearance, aggregate content, potency, and lot consistency.

Entry route	Hizentra relevance	Entry barrier
ANDA generic	Generally unavailable for a biologic	Product classification
351(k) biosimilar	Principal competing route	Clinical, analytical, manufacturing, and regulatory burden
351(a) biologic	Possible but less efficient	Full biologic development program
Compounded product	Not a practical substitute	Sterility, potency, and biologic handling constraints
Alternative SCIG product	Direct commercial competitor	Requires independent approval and supply chain

The largest barriers are not excipient cost. They are plasma supply, manufacturing scale, comparability, clinical evidence, and market access. A biosimilar with a different excipient system may face additional development work if excipient differences affect immunogenicity, tolerability, viscosity, stability, or device compatibility.

How does Hizentra compare with competing immunoglobulin products?

Hizentra competes with other subcutaneous immunoglobulin products and with intravenous immunoglobulin products.

Product type	Typical formulation profile	Commercial advantage	Limitation
Hizentra	20% liquid, L-proline and polysorbate 80	High concentration, room-temperature handling, self-administration	Frequent administration and injection-site burden
Other 20% SCIG products	Product-specific stabilizer and surfactant systems	Similar home-treatment proposition	Differentiation depends on tolerability, device, dosing, and access
10% SCIG products	Lower concentration liquid	May offer different tolerability or dosing characteristics	Higher dose volume
IVIG	Intravenous liquid or lyophilized product	Hospital and infusion-center familiarity	Venous access, systemic peak exposure, and facility dependence

The formulation itself is difficult to differentiate in the prescriber’s mind unless it changes the patient experience. Commercial claims are more likely to center on reduced volume, fewer site changes, pump usability, room-temperature handling, injection-site reactions, and patient independence.

What commercial opportunities exist in Hizentra excipients?

Pharmaceutical-grade L-proline supply

L-proline suppliers can compete for qualified-source status by offering high-purity material, reliable global production, low impurity variability, and strong regulatory files. The opportunity is recurring but qualification-intensive. Once approved, replacement is difficult because a source change may trigger comparability work and regulatory reporting.

Polysorbate 80 quality platforms

The strongest opportunity is in high-control polysorbate 80 products with defined peroxide, hydrolysis, and fatty-acid profiles. Suppliers can create value through:

• Pharmaceutical-grade documentation.
• Low-oxidation manufacturing.
• Improved analytical characterization.
• Global pharmacopoeial compliance.
• Supply-security programs.
• Container and closure compatibility packages.

Polysorbate alternatives such as polysorbate 20 or nonionic surfactants may be technically attractive, but substitution in a commercial immunoglobulin product would require extensive stability and comparability assessment.

High-concentration immunoglobulin formulation services

Contract development and manufacturing organizations can support next-generation SCIG products through:

• Protein-stability screening.
• Excipient-combination studies.
• Viscosity reduction.
• Low-volume delivery design.
• Container-closure compatibility.
• Freeze-thaw and agitation studies.
• Extractables and leachables testing.
• Subcutaneous tolerability assessment.

The commercial objective is to preserve a 20% or higher protein concentration while reducing injection pain, infusion time, and device burden.

Device-linked formulation opportunities

Hizentra’s commercial model is closely connected to pumps, infusion sets, syringes, and wearable delivery systems. A formulation with lower viscosity or greater shear stability could enable smaller pumps, faster administration, fewer infusion sites, or larger-volume wearable systems.

Device patents may create a separate barrier even when a competitor designs around formulation claims. Companies that combine a stable high-concentration SCIG formulation with a proprietary delivery device may create a stronger overall product position than companies competing solely on excipients.

Biosimilar formulation design

A biosimilar sponsor can use excipient strategy to avoid reference-product claims while preserving comparable product performance. Potential approaches include:

• Replacing L-proline with another stabilizer.
• Modifying polysorbate concentration.
• Using a different surfactant.
• Adjusting pH within a clinically acceptable range.
• Changing container or delivery system.
• Developing a formulation optimized for a proprietary wearable injector.

Each change creates a regulatory burden. The commercial value comes from avoiding patent claims or improving the patient-use profile, not from reducing excipient cost alone.

What geographic opportunities exist for Hizentra-related excipients?

The United States, European Union, Japan, and other regulated markets require robust excipient qualification and change-control systems. Global suppliers can capture value by aligning one excipient platform with multiple pharmacopoeias and regulatory expectations.

Emerging opportunities include:

• Regional second-source qualification.
• Local manufacturing for supply resilience.
• Excipient production near biologics manufacturing hubs.
• Temperature-resilient distribution for home-infusion markets.
• Regulatory support for markets where SCIG adoption is expanding.

The geographic opportunity is strongest where subcutaneous immunoglobulin use is moving from hospitals to home care. That transition increases demand for room-temperature stability, simpler administration, specialty-pharmacy logistics, and patient-support services.

How strong is the Hizentra patent estate?

Hizentra’s commercial protection is best characterized as a layered biologic estate rather than a single dominant composition-of-matter patent. Strength is likely to vary across formulation, use, manufacturing, and device claims.

Estate component	Strategic strength
Human immunoglobulin composition	Limited conventional composition-of-matter exclusivity
High-concentration formulation	Potentially important, but vulnerable to design-around
L-proline and polysorbate system	Relevant to formulation claims and biosimilar strategy
CIDP method of use	Potentially important for indication-specific launch planning
Plasma-derived manufacturing	Strong practical barrier, even without broad patent protection
Delivery devices	Can create additional litigation and licensing exposure
Regulatory exclusivity	Original biologic period has elapsed

Manufacturing know-how may be more commercially durable than individual excipient patents. Plasma sourcing, purification yield, viral-clearance validation, aggregate control, and lot-release methods are difficult to replicate quickly and may remain protected through trade secrets and operational scale.

What litigation and settlement issues affect Hizentra?

The most relevant litigation risks concern biosimilar patent disputes, manufacturing patents, formulation claims, and device rights. Because Hizentra is a biologic, litigation may proceed through BPCIA-related exchanges and patent actions rather than the standard Hatch-Waxman Paragraph IV model.

Potential settlement terms may include:

• Delayed biosimilar entry.
• License rights for a specified launch date.
• Geographic limitations.
• Carve-outs for CIDP or primary immunodeficiency.
• Restrictions on interchangeable substitution.
• Cross-licenses for formulation or device technology.

A settlement can materially alter launch timing even after regulatory approval. Commercial analysis should therefore treat FDA approval, patent clearance, settlement terms, and manufacturing readiness as separate milestones.

Key Takeaways

• Hizentra is a 20% subcutaneous immunoglobulin product formulated with L-proline, polysorbate 80, and water for injection.
• L-proline supports high-concentration protein stability; polysorbate 80 limits adsorption and aggregation.
• The excipient system supports room-temperature storage, ready-to-use administration, and home infusion.
• Hizentra is regulated as a biologic. Conventional ANDA generic substitution and ordinary Paragraph IV analysis do not apply.
• The original biologic exclusivity period tied to the 2010 approval has elapsed, but biosimilar entry still faces manufacturing, patent, and supply barriers.
• The most valuable commercial opportunities are pharmaceutical-grade excipient supply, polysorbate quality control, high-concentration SCIG development, wearable delivery systems, and biosimilar formulation design.
• Manufacturing know-how and plasma supply are likely to be as important as formal formulation patents.
• The strongest competitive differentiation is likely to come from injection volume, infusion speed, device usability, tolerability, and patient-support infrastructure.

FAQs

Can L-proline be replaced in a Hizentra biosimilar?

Yes, a biosimilar developer may use a different stabilizer if the resulting product meets analytical, stability, safety, and clinical comparability requirements. The replacement may also help avoid formulation patent claims.

Does Hizentra contain sucrose?

No. The FDA label identifies L-proline and polysorbate 80 as the principal inactive formulation ingredients, with water for injection as the vehicle.[1]

Is Hizentra refrigerated?

Hizentra is labeled for storage at room temperature up to the specified temperature limit and storage duration. This supports specialty-pharmacy and home-infusion distribution without routine refrigerated handling.[1]

Can a generic company file an ANDA for Hizentra?

No conventional ANDA route is generally available for Hizentra because it is a biologic. A competing sponsor would typically evaluate a 351(k) biosimilar application or another biologic approval pathway.

Which excipient creates the greatest formulation-control risk?

Polysorbate 80 generally creates the greater analytical-control burden because oxidation and hydrolysis can affect protein quality and product stability. L-proline remains important for stabilization and high-concentration formulation performance.

References

1. U.S. Food and Drug Administration. (2023). Hizentra (immune globulin subcutaneous [human], 20% liquid) prescribing information. CSL Behring LLC.

2. U.S. Food and Drug Administration. (2010). FDA approves Hizentra for primary immunodeficiency diseases. FDA.

3. U.S. Food and Drug Administration. (2018). FDA approves Hizentra for maintenance therapy in chronic inflammatory demyelinating polyneuropathy. FDA.

4. U.S. Food and Drug Administration. (n.d.). Purple Book: Database of licensed biological products. FDA.

5. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA.

6. Biologics Price Competition and Innovation Act of 2009, 42 U.S.C. § 262.